Skip to content


Aqilion runs four innovative programs

The Aqilion team and network has extensive expertise and experience in inflammation. The company runs four innovative R&D programs. The Regulus program is the most advanced and Aqilion started a Phase 1 safety study in healthy volunteers in August 2022, to be followed by a Phase 2a study in patients. The Girtab program is in preclinical stage and Alnitak and Polaris programs are in discovery phase.

All four in-house programs fit the collective experience of the Aqilion team and allow us to make optimal use of the expertise of our network and partners.